Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Molecular and Oxford GlycoSciences Pen Research Agreement

Premium

OXFORD--Oxford Molecular Group announced it reached an agreement jointly with its associate companies, Cambridge Combinatorial and Cambridge Drug Discovery, to provide research services and consulting in drug design, combinatorial chemistry, and high-throughput screening to Oxford GlycoScience. The research program will initially target the design and synthesis of inhibitors of carbohydrate-processing enzymes. Oxford Molecular will use its software and discovery expertise to design multiple novel combinatorial libraries, which Cambridge Combinatorial will synthesize for screening by Cambridge Drug Discovery to identify potential drugs. Oxford Molecular and Cambridge Combinatorial have also agreed to provide consultancy services in information technology and combinatorial chemistry to Oxford GlycoScience.

Filed under

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.